SLN Stock: Price, Earnings History and SEC Filings
Silence Therapeutics plc (SLN) last traded at $19.75, down 0.25% on the latest session and up 80.7% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.26 against an analyst estimate of $-0.32, a beat of 18.8%.
$19.75 -0.25%
1 month+80.70%
52-week high$19.87
52-week low$4.19
Volume621,426
ExchangeNasdaqGM
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
SLN earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 10, 2026 | $-0.26 | $-0.32 | +18.75% |
| Mar 2026 | May 7, 2026 | $-0.32 | $-0.33 | +3.03% |
| Dec 2025 | Mar 5, 2026 | $-0.25 | $-0.32 | +21.88% |
| Sep 2025 | Nov 6, 2025 | $-0.45 | $-0.40 | -12.50% |
SLN beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for SLN
SEC filing data is not available right now. You can search for SLN on SEC EDGAR.
SLN news
- A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on MondayOct 20, 2026 · finance.yahoo.com
- Does Silence Therapeutics (SLN) Have the Potential to Rally 82.84% as Wall Street Analysts Expect?Oct 20, 2026 · finance.yahoo.com
- Is Silence Therapeutics (NasdaqGM:SLN) Reasonable Near Its $20 Deal Price?Oct 20, 2026 · finance.yahoo.com
- Silence Therapeutics (SLN) Gets 130% Premium Offer From Merck, Shares Surge Over 100%Oct 19, 2026 · finance.yahoo.com
- Merck KgaA Is Paying More Than Double for This Gene-Silencing Biotech, Which Is Soaring 125%Oct 19, 2026 · finance.yahoo.com
- Silence Therapeutics jumps 59% on Merck takeoverOct 19, 2026 · proactiveinvestors.com
- Silence Therapeutics stock soars 125% on Merck acquisitionOct 19, 2026 · finance.yahoo.com
- Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, GermanyOct 19, 2026 · finance.yahoo.com
About Silence Therapeutics plc
Silence Therapeutics plc (SLN) is a US-listed public company on Nasdaq.